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ABSTRACT
Background and Objectives: Antithrombotic therapy after percutaneous coronary 
intervention (PCI) in patients with atrial fibrillation (AF) has changed in recent years with 
new data from large randomized trials and updates to clinical guidelines. This study aimed to 
investigate the trends in periprocedural antithrombotic regimens in Korean patients with AF 
undergoing PCI with non-vitamin K antagonist oral anticoagulants (NOACs).
Methods: Using the claims database of the Health Insurance Review and Assessment during 
2013–2018, 27,594 patients with AF undergoing PCI were identified. The annual prevalence 
of PCI and prescriptions of each antithrombotic agent, including antiplatelet agents and oral 
anticoagulants, within 30 days after PCI were investigated.
Results: During 2013–2018, the number of patients with AF undergoing PCI increased up 
to 1.3-fold (from 3,913 to 5,075 patients per year). After the introduction of NOACs, the 
proportion of dual antiplatelet therapy (DAPT) decreased from 71.9% to 49.8% but still 
occupied the largest proportion among antithrombotic regimens. Triple antithrombotic 
therapy (TAT) use increased from 25.4% to 46.0%, and NOAC has rapidly replaced warfarin 
as the oral anticoagulant of choice. TAT was preferred to DAPT for patients with CHA2DS2-
VASc score ≥2. Among various factors, prior intracranial hemorrhage was the most powerful 
predictor of favoring DAPT use over TAT.
Conclusion: Since the introduction of NOACs, the patterns of periprocedural antithrombotic 
regimens have changed rapidly toward more use of TAT, specifically with NOAC-based 
regimen. Appropriate stroke prevention with oral anticoagulants is still underutilized in 
patients with AF undergoing PCI in Korea.
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Anticoagulant drugs
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INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and stroke prevention 
with oral anticoagulation (OAC) is central to its management when stroke risk factors are 
present.1) With the advent of the non-vitamin K antagonist oral anticoagulants (NOACs), 
the perspective for stroke prevention in AF has changed.2) Coronary artery disease (CAD) is 
reported in 20%–40% of AF patients.3) Over the lifetime course, 5–15% of AF patients are 
known to receive percutaneous coronary intervention (PCI), and 5–10% of PCI patients have 
concomitant AF.4) Although OAC therapy is recommended to reduce the risk of ischemic 
stroke in patients with AF, dual antiplatelet therapy (DAPT) is recommended to reduce 
the risk of stent thrombosis in patients undergoing PCI. However, such a combination of 
antiplatelet agents and antithrombotic therapy with OAC may increase the risk of bleeding.
Recently, major clinical trials have reported the benefits of NOAC-based double 
antithrombotic therapy (DAT) over warfarin-based triple antithrombotic therapy (TAT) in AF 
patients with CAD undergoing PCI.5-8) Hence, international guidelines have updated their 
recommendations based on these trials.1)9-11)
Despite the rapidly evolving evidence-based strategies of antithrombotic therapy in AF 
patients with PCI, appropriate antithrombotic regimens are suboptimally prescribed in 
real-world practice, specifically in Asia. A previous study reported high rates of antiplatelet 
use and underutilization of OAC use in Korean AF patients after PCI.12) One possible reason 
is that Asian patients with AF are known to have higher risks of stroke and bleeding than 
non-Asian patients.13) Also, Asians are perceived to have a higher risk of bleeding for both 
antiplatelet agents and oral anticoagulants compared to non-Asians.14) In the REDUAL-PCI 
trial, the Japanese subgroup had a higher rate of International Society on Thrombosis and 
Haemostasis major or clinically relevant non-major bleeding, while a lower rate of myocardial 
infarction (MI) or stent thrombosis than the overall population.15) Therefore, there is the 
need to investigate the status of antithrombotic therapy in ‘real-world’ practice in Asian AF 
patients treated with PCI.
This study aimed to investigate how periprocedural antithrombotic regimens have been 
changed since the introduction of NOACs among Korean patients with AF undergoing PCI.
METHODS
This was a retrospective cross-sectional study using the claims database from the Health 
Insurance Review and Assessment (HIRA) during 2013–2018. The HIRA database provides 
medical claims information on the entire Korean population.16) Its database comprises 
not only comprehensive claims information on prescriptions and procedures but also 
demographic data of each insured member. The HIRA database also has the disease status of 
each member encoded in the International Classification of Disease, Tenth Revision, Clinical 
Modification.16) The data can be provided to researchers for academic purposes upon request. 
This study was approved by the Seoul National University Hospital Institutional Review Board 
(IRB) (IRB No. E-1911-052-1078), and the informed consent was waived by the review board 
due to the anonymized characteristics of the data. The study was conducted according to the 
ethical guidelines of the Declaration of Helsinki revised in 2013.
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Study population and definitions
From the claims database, we identified the patients with AF undergoing PCI during 
2013–2018. We used well-defined operational definitions for AF and PCI validated in a 
previous study.16) AF was defined as having diagnostic codes of I48.0-48.4 or I48.9 during 
hospitalization or outpatient clinics. PCI was defined as having procedural codes of M6551, 
M6552, M6561-6564, M6571, and M6572. Study subjects were defined as those who had AF 
before PCI. Finally, we excluded patients with mitral stenosis (I50, I52, and I59) or prosthetic 
heart valves (Z952-Z954).
Using diagnostic codes, we defined several study variables of comorbidities, including 
hypertension, diabetes mellitus, dyslipidemia, peripheral arterial disease, ischemic stroke, 
systemic thromboembolism, intracranial hemorrhage, gastrointestinal bleeding, renal 
disease, and liver disease.16) Their details are presented in Supplementary Table 1. To evaluate 
the risks of ischemic stroke and bleeding, we used the CHA2DS2-VASc and HAS-BLED scores, 
respectively.17) HAS-BLED scores were calculated without international normalized ratio, 
and the amount of alcohol consumption as such information was not available in the HIRA 
database.2) High risk of ischemic stroke or bleeding was defined as a CHA2DS2-VASc score ≥2 
or HAS-BLED score ≥3, respectively.
Antithrombotic regimens
We examined the claims data for antithrombotic agents prescribed outpatient or inpatient for 
each patient. For antithrombotic agents, we included aspirin, clopidogrel, prasugrel, ticagrelor, 
warfarin, and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban). In Korea, NOAC was 
fully reimbursed after July 2015; thus, the prescription of NOAC has dramatically increased 
since then. The antithrombotic regimen was evaluated within 30 days after receiving PCI. The 
prescription period of interest was limited in the present study because this study aimed to 
examine the pattern of the management for antithrombotic therapy early after PCI.
We classified antithrombotic regimens according to the combination of prescribed agents 
into single antiplatelet therapy, DAPT, DAT (warfarin or NOAC-based), and TAT (warfarin 
or NOAC-based). Meanwhile, multiple combinations of antithrombotic prescriptions may 
be present in a patient within 30 days of PCI, in which case, the prescription comprising the 
maximum combination was selected.
Statistical analyses
The annual number of patients with AF undergoing PCI was investigated. The baseline 
characteristics, including age, sex, comorbidities, CHA2DS2-VASc, and HAS-BLED scores of 
the annual population, were evaluated. Data are presented as number (%) for dichotomous 
or categorical variables and as mean±standard deviation for continuous variables. The 
significance of a temporal trend of each study variable was analyzed using linear regression 
analysis over the study period. To investigate whether there were significant interactions 
between antithrombotic regimens and subgroups, we performed subgroup analyses for sex, 
high risks of ischemic stroke, and bleeding. We also performed a subgroup analysis for those 
hospitalized due to MI. MI was defined by having a primary diagnostic code of either I21 or 
I22 for hospitalization. This operational definition of MI has been validated to have a positive 
predictive value of 92% in our previous study.18) To evaluate the independent predictors of 
favoring TAT over DAPT, we performed multivariate logistic regression analysis. Moreover, 
multivariate logistic regression analysis was performed to investigate the differences in the 
preference of TAT over DAPT across the scores of CHA2DS2-VASc or HAS-BLED. All analyses 
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were considered as statistically significant if the two-tailed p-value was less than 0.05. All 
statistical analyses were performed using the Statistical Analysis System (SAS) version 9.3 
(SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 27,594 patients with AF undergoing PCI were identified using the claims database 
from 2013 to 2018. Table 1 presents the baseline characteristics of the study population. 
The number of patients with AF undergoing PCI has generally increased from 3,913 in 
2013 to 5,075 in 2018 (Figure 1). Moreover, the number of patients who had coronary stent 
implantation increased from 3,380 (86.4%) in 2013 to 4,432 (87.3%) in 2018, whereas the 
number of PCI procedures per patients has remained stationary (1.0±0.2 per patient). 
From 2013 to 2018, the mean age has increased from 69.4 to 71.3 years (p for trend <0.001), 
whereas the proportion of females decreased from 35.2% to 30.7% (p for trend <0.001).
Among the various comorbidities, the prevalence of dyslipidemia, congestive heart failure, and 
renal and liver diseases increased over the years, while that of MI, intracranial hemorrhage, 
and gastrointestinal bleeding decreased (p for trend <0.001 in all cases except intracranial 
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Table 1. Baseline characteristics of the study population
Years 2013 2014 2015 2016 2017 2018 p for trend
Demographics
Patients with AF undergoing PCI 3,913 4,118 4,460 5,133 4,895 5,075
Patients with AF undergoing PCI with stents 3,380 3,501 3,844 4,450 4,327 4,432
PCI procedures 4,026 4,244 4,623 5,300 5,052 5,209
PCI procedures with stent 3,432 3,567 3,928 4,548 4,424 4,507
PCI procedures per patient 1.0±0.2 1.0±0.2 1.0±0.2 1.0±0.2 1.0±0.2 1.0±0.2
Female 1,377 (35.2) 1,387 (33.7) 1,508 (33.8) 1,710 (33.3) 1,615 (33.0) 1,556 (30.7) <0.001
Age (years) 69.4±10.5 69.9±10.8 70.2±10.6 70.6±10.4 71.0±10.2 71.3±10.1 <0.001
Age strata
65–74 years 1,445 (36.9) 1,383 (33.6) 1,462 (32.8) 1,693 (33.0) 1,587 (32.4) 1,581 (31.2)
≥75 years 1,344 (34.3) 1,566 (38.0) 1,750 (39.2) 2,058 (40.1) 2,036 (41.6) 2,234 (44.0)
Comorbidities
Hypertension 3,516 (89.9) 3,719 (90.3) 4,009 (89.9) 4,620 (90.0) 4,398 (89.8) 4,586 (90.4) 0.715
Diabetes mellitus 1,640 (41.9) 1,675 (40.7) 1,827 (41.0) 2,040 (39.7) 2,084 (42.6) 2,151 (42.4) 0.206
Dyslipidemia 3,216 (82.2) 3,520 (85.5) 3,912 (87.7) 4,479 (87.3) 4,342 (88.7) 4,513 (88.9) <0.001
Congestive heart failure 1,543 (39.4) 1,810 (44.0) 2,033 (45.6) 2,525 (49.2) 2,631 (53.7) 2,735 (53.9) <0.001
MI 1,565 (40.0) 1,740 (42.3) 1,930 (43.3) 2,252 (43.9) 1,873 (38.3) 1,878 (37.0) <0.001
Peripheral arterial disease 1,051 (26.9) 1,111 (27.0) 1,217 (27.3) 1,514 (29.5) 1,505 (30.7) 1,630 (32.1) <0.001
Ischemic stroke 488 (12.5) 512 (12.4) 476 (10.7) 541 (10.5) 507 (10.4) 565 (11.1) 0.993
Intracranial hemorrhage 49 (1.3) 27 (0.7) 22 (0.5) 35 (0.7) 26 (0.5) 35 (0.7) 0.009
Gastrointestinal bleeding 333 (8.5) 353 (8.6) 355 (8.0) 394 (7.7) 354 (7.2) 376 (7.4) 0.004
Renal disease 786 (20.1) 838 (20.3) 949 (21.3) 1,137 (22.2) 1,148 (23.5) 1,235 (24.3) <0.001
Liver disease 1,379 (35.2) 1,491 (36.2) 1,748 (39.2) 2,070 (40.3) 2,015 (41.2) 2,164 (42.6) <0.001
CHA2DS2-VASc score
Mean 3.7±1.8 3.8±1.9 3.0±1.9 3.9±1.9 3.9±1.9 4.0±1.9 <0.001
Low (0–1) 427 (10.9) 430 (10.4) 461 (10.3) 487 (9.5) 439 (9.0) 434 (8.6)
High (≥2) 3,486 (89.1) 3,688 (89.6) 3,999 (89.7) 4,646 (90.5) 4,456 (91.0) 4,641 (91.5)
HAS-BLED score
Mean 3.3±1.1 3.4±1.1 3.4±1.0 3.4±1.0 3.4±1.0 3.5±1.0 <0.001
Low (0–1) 112 (2.9) 132 (3.2) 103 (2.3) 127 (2.5) 105 (2.1) 106 (2.1)
Intermediate (2) 669 (17.1) 645 (15.7) 713 (16.0) 716 (13.9) 701 (14.3) 659 (13.0)
High (≥3) 3,132 (80.0) 3,341 (81.1) 3,644 (81.7) 4,290 (83.6) 4,089 (83.5) 4,310 (84.9)
Data are presented as number (%) or mean±standard deviation.
AF = atrial fibrillation; MI = myocardial infarction; PCI = percutaneous coronary intervention.
hemorrhage [p for trend =0.009] and gastrointestinal bleeding [p for trend =0.004]). Overall, 
both the CHA2DS2-VASc and HAS-BLED scores increased from 3.7±1.8 and 3.3±1.1 in 2013 to 
4.0±1.9 and 3.5±1.0 in 2018, respectively (p for trend <0.001 for both scores). During the study 
period, patients with CHA2DS2-VASc scores ≥2 increased from 89.1% to 91.5% and those with 
HAS-BLED scores ≥3 increased from 80.0% to 84.9% (Figure 1).
Trends in antithrombotic prescriptions among patients with atrial fibrillation 
undergoing percutaneous coronary intervention
Table 2 presents detailed data for the annual proportions of each antithrombotic prescription 
among patients with AF undergoing PCI. During the study period, DAPT significantly 
decreased from 2,815 (71.9%) to 2,525 (49.8%), whereas TAT increased from 995 (25.4%) to 
2,335 (46.0%) (both p for trend <0.001) (Figure 2). Such an increase in TAT was dominated 
by NOAC-based regimens (from 39 [1.0%] to 2027 [39.9%]). In contrast, warfarin-based 
regimens diminished from 956 (24.4%) to 308 (6.1%). For NOAC-based regimens, we 
evaluated the annual proportions of both regular- and reduced-dose NOAC regimens. The 
prescription of reduced-dose NOACs was increased from 57.5% to 81.4% from 2013 to 2018 
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Figure 1. Temporal trends of patients with AF undergoing PCI after introduction of NOAC. 
AF = atrial fibrillation; NOAC = non-vitamin K oral anticoagulant; PCI = percutaneous coronary intervention.
Table 2. Temporal trends of antithrombotic regimens among patients with AF undergoing PCI
Year 2013 2014 2015 2016 2017 2018 p for trend
Patients with AF undergoing PCI 3,913 4,118 4,460 5,133 4,895 5,075
Triple therapy (NOAC) 39 (1.0) 29 (0.7) 358 (8.0) 1,180 (23.0) 1,498 (30.6) 2,027 (39.9) <0.001
Triple therapy (warfarin) 956 (24.4) 1,031 (25.0) 835 (18.7) 603 (11.7) 405 (8.3) 308 (6.1) <0.001
Double therapy (NOAC) 1 (0.0) 1 (0.0) 10 (0.2) 48 (0.9) 62 (1.3) 115 (2.3) <0.001
Double therapy (warfarin) 25 (0.6) 29 (0.7) 30 (0.7) 10 (0.2) 14 (0.3) 10 (0.2) <0.001
DAPT 2,815 (71.9) 2,933 (71.2) 3,144 (70.5) 3,200 (62.3) 2,809 (57.4) 2,525 (49.8) <0.001
SAPT 50 (1.3) 70 (1.7) 51 (1.1) 53 (1.0) 71 (1.5) 58 (1.1) 0.284
No antithrombotic therapy 27 (0.7) 25 (0.6) 29 (0.7) 35 (0.7) 26 (0.5) 28 (0.6) 0.359
Patients with NOAC-based regimens 40 30 368 1,228 1,560 2,142
Patients with regular-dose NOAC 17 (42.5) 15 (50) 113 (30.7) 246 (20) 277 (17.8) 398 (18.6) <0.001
Patients with reduced-dose NOAC 23 (57.5) 15 (50.0) 255 (69.3) 982 (80.0) 1,283 (82.2) 1,744 (81.4) <0.001
Data are presented as number (%).
AF = atrial fibrillation; DAPT = dual antiplatelet therapy; NOAC = non-vitamin K antagonist oral anticoagulant; PCI = percutaneous coronary intervention; SAPT = 
single antiplatelet therapy.
(Table 2). Among the different regimens, DAPT was the most common, regardless of the 
period in both sexes, in those with CHA2DS2-VASc scores ≥2, and in those with HAS-BLED 
scores ≥3 (Table 3).
The results of subgroup analysis for patients hospitalized due to MI are presented in 
Supplementary Table 2. Generally, the temporal trends of antithrombotic regimens in those 
6/14https://e-kcj.org https://doi.org/10.4070/kcj.2020.0407































































































































































































Figure 2. Temporal trends of antithrombotic regimens in patients with AF undergoing PCI after introduction of NOAC. 
AF = atrial fibrillation; DAPT = dual antiplatelet therapy; NOAC = non-vitamin K oral anticoagulant; PCI = percutaneous coronary intervention.
with or without MI were similar. However, compared to patients without MI, those with MI 
had a higher proportion of DAPT and low proportions of TAT and DAT consistently over the 
study period. This finding may suggest that, if a patient with AF is hospitalized due to acute 
coronary syndrome, then the patient may have more attention to the management for acute 
coronary syndrome than for AF.
We also evaluated the annual trends of each NOAC type and P2Y12 inhibitor (Supplementary 
Tables 3 and 4). From 2013 to 2018, dabigatran uses decreased from 75.6% to 7.9%, 
while apixaban and edoxaban increased to 34.3% and 24.2%, respectively. In summary, 
both rivaroxaban and apixaban are the two most preferred NOACs. For P2Y12 inhibitors, 
clopidogrel was the most preferred choice, while prasugrel was the least used. From 2013 
to 2018, the proportion of ticagrelor use has been substantially increased, although the 
combination of NOAC and ticagrelor was not recommended in the guidelines.11)
Predictors of favoring triple antithrombotic therapy over dual antiplatelet 
therapy
Multivariate logistic regression analysis was performed to evaluate the predictors favoring 
TAT over DAPT. Among the covariates, the most significant predictor of TAT was age ≥75 
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Table 3. Subgroup analyses for the temporal trends of antithrombotic regimens
Year 2013 2014 2015 2016 2017 2018 p for trend
Male 2,536 2,731 2,952 3,423 3,280 3,519
Triple therapy (NOAC) 23 (0.9) 15 (0.5) 221 (7.5) 758 (22.1) 1,003 (30.6) 1,384 (39.3) <0.001
Triple therapy (warfarin) 630 (24.8) 648 (23.7) 561 (19.0) 410 (12.0) 288 (8.8) 232 (6.6) <0.001
Double therapy (NOAC) 1 (0.0) 1 (0.0) 6 (0.2) 29 (0.8) 49 (1.5) 74 (2.1) <0.001
Double therapy (warfarin) 14 (0.6) 20 (0.7) 22 (0.7) 7 (0.2) 11 (0.3) 8 (0.2) <0.001
DAPT 1,817 (71.6) 1,982 (72.6) 2,083 (70.6) 2,152 (62.9) 1,865 (56.9) 1,754 (49.8) <0.001
SAPT 32 (1.3) 47 (1.7) 39 (1.3) 38 (1.1) 40 (1.2) 45 (1.3) 0.350
No antithrombotic therapy 19 (0.7) 18 (0.7) 20 (0.7) 26 (0.8) 18 (0.5) 20 (0.6) 0.343
Female 1,377 1,387 1,508 1,710 1,615 1,556
Triple therapy (NOAC) 16 (1.2) 14 (1.0) 137 (9.1) 422 (24.7) 495 (30.7) 643 (41.3) <0.001
Triple therapy (warfarin) 326 (23.7) 383 (27.6) 274 (18.2) 193 (11.3) 117 (7.2) 76 (4.9) <0.001
Double therapy (NOAC) 0 (0) 0 (0) 4 (0.3) 19 (1.1) 13 (0.8) 41 (2.6) <0.001
Double therapy (warfarin) 11 (0.8) 9 (0.6) 8 (0.5) 3 (0.2) 3 (0.2) 2 (0.1) <0.001
DAPT 998 (72.5) 951 (68.6) 1,061 (70.4) 1,048 (61.3) 944 (58.5) 771 (49.6) <0.001
SAPT 18 (1.3) 23 (1.7) 12 (0.8) 15 (0.9) 31 (1.9) 13 (0.8) 0.578
No antithrombotic therapy 8 (0.6) 7 (0.5) 9 (0.6) 9 (0.5) 8 (0.5) 8 (0.5) 0.781
Patients with high risk of systemic 
thromboembolism*
3,486 3,688 3,999 4,646 4,456 4,641
Triple therapy (NOAC) 38 (1.1) 28 (0.8) 337 (8.4) 1,115 (24.0) 1,412 (31.7) 1,904 (41.0) <0.001
Triple therapy (warfarin) 870 (25.0) 952 (25.8) 775 (19.4) 550 (11.8) 371 (8.3) 284 (6.1) <0.001
Double therapy (NOAC) 1 (0.0) 1 (0.0) 9 (0.2) 45 (1.0) 54 (1.2) 107 (2.3) <0.001
Double therapy (warfarin) 21 (0.6) 24 (0.7) 26 (0.7) 10 (0.2) 11 (0.2) 10 (0.2) <0.001
DAPT 2,489 (71.4) 2,598 (70.4) 2,783 (69.6) 2,836 (61.0) 2,509 (56.3) 2,254 (48.6) <0.001
SAPT 43 (1.2) 63 (1.7) 40 (1.0) 52 (1.1) 68 (1.5) 54 (1.2) 0.617
No antithrombotic therapy 24 (0.7) 22 (0.6) 26 (0.7) 34 (0.7) 22 (0.5) 24 (0.5) 0.276
Patients with high risk of bleeding† 3,132 3,341 3,644 4,290 4,089 4,310
Triple therapy (NOAC) 36 (1.1) 27 (0.8) 313 (8.6) 1,040 (24.2) 1,313 (32.1) 1,778 (41.3) <0.001
Triple therapy (warfarin) 802 (25.6) 875 (26.2) 723 (19.8) 508 (11.8) 348 (8.5) 256 (5.9) <0.001
Double therapy (NOAC) 1 (0.0) 0 (0) 10 (0.3) 46 (1.1) 52 (1.3) 102 (2.4) <0.001
Double therapy (warfarin) 21 (0.7) 27 (0.8) 24 (0.7) 9 (0.2) 12 (0.3) 8 (0.2) <0.001
DAPT 2,207 (70.5) 2,331 (69.8) 2,507 (68.8) 2,606 (60.7) 2,278 (55.7) 2,091 (48.5) <0.001
SAPT 43 (1.4) 59 (1.8) 41 (1.1) 48 (1.1) 61 (1.5) 50 (1.2) 0.243
No antithrombotic therapy 22 (0.7) 22 (0.7) 23 (0.6) 29 (0.7) 17 (0.4) 21 (0.5) 0.092
Data are presented as number (%).
DAPT = dual antiplatelet therapy; NOAC = non-vitamin K antagonist oral anticoagulant; SAPT = single antiplatelet therapy.
*Patients with CHA2DS2-VASc score ≥2; †Patients with HAS-BLED score ≥3.
years (odds ratio [OR], 1.890; 95% confidence interval [CI], 1.576–2.267). Other significant 
predictors included age of 65–74 years, congestive heart failure, CHA2DS2-VASc scores ≥2, 
hypertension, and systemic thromboembolic events (Figure 3). Factors favoring DAPT over 
TAT included female sex, peripheral arterial disease, MI, dyslipidemia, renal disease, and 
intracranial hemorrhage. Among those factors, intracranial hemorrhage was the most potent 
predictor favoring DAPT (OR, 0.375; 95% CI, 0.170–0.827). Presence of diabetes mellitus and 
high bleeding risk (HAS-BLED score ≥3) did not show a significant preference for either of 
the 2 regimens.
Impacts of thromboembolic or bleeding risks on antithrombotic 
prescriptions
Taking the patients with low-risk CHA2DS2-VASc score (0 in males and 1 in females) as the 
reference, those with higher scores showed a non-significant preference for TAT over DAPT 
(Figure 4). For the case of the risk of bleeding, compared to the patients with a HAS-BLED 
score of 0 or 1, those with higher scores showed a non-significant preference of DAPT over TAT.
DISCUSSION
This study investigated the trends of periprocedural antithrombotic therapy in patients with 
AF undergoing PCI using the claims database in the NOAC era. Our principal findings are 
as follows: (i) the number of Korean patients with AF undergoing PCI has been substantially 
increased after the introduction of NOACs in 2013; (ii) the risk profile for both ischemic 
stroke and bleeding of these patients has been increasing annually; (iii) periprocedural 
antithrombotic regimen has shifted from DAPT-based to NOAC-based TAT, but DAPT was 
still the most favored antithrombotic therapy; (iv) the predictors of underuse of TAT were 
intracranial hemorrhage, renal disease, dyslipidemia, MI, peripheral arterial disease, and 
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Figure 3. Multivariate logistic regression analysis for factors associated with prescriptions of triple therapy. 
CI = confidence interval; DAPT = dual antiplatelet therapy; OR = odds ratio; TIA = transient ischemic attack.
female sex; and (v) TAT or DAPT was seemed to be preferred in the case of a high risk of 
ischemic stroke or bleeding, respectively, although this trend was not statistically significant.
This study has the following main strengths: it evaluated AF-PCI patients on a national scale 
and, to the best of our knowledge, included the largest number of patients. The management 
of AF-PCI patients has been rapidly evolving in recent years as NOACs were introduced, but 
detailed temporal trend data on real-world clinical practice have been relatively rare. This study 
illustrates a clear gap between guideline recommendations and real-world clinical practice.
Before 2016, studies on antithrombotic therapy in AF-PCI patients had investigated the 
combination therapy of warfarin and antiplatelet drugs. The WOEST trial19) compared 
bleeding events 1 year after PCI between the TAT group treated with warfarin, aspirin, and 
clopidogrel and the DAT group treated with warfarin and clopidogrel. This trial found that 
compared to TAT, DAT significantly reduced the risk of bleeding without increasing the risk 
of thrombotic events. A Danish nationwide cohort study reported that warfarin-based DAT 
showed a lower risk of bleeding than TAT, without increasing the risk of ischemic events.20)
Since 2016, studies have been focused on using combination therapy of NOAC and antiplatelet 
drugs. Clinical trials, including PIONEER AF-PCI,5) RE-DUAL PCI,6) AUGUSTUS,7) and 
ENTRUST-AF-PCI,8) studied DAT based on rivaroxaban, dabigatran, apixaban, and edoxaban, 
respectively. Although the study designs were different, NOAC-based DAT was associated with 
a lower risk of bleeding without increasing the risk of ischemic events compared to warfarin-
based TAT.21)22) Accordingly, various international guidelines have been updated.1)9-11)
All the guidelines largely advocate approaches that have more similarities than differences. 
First, a thorough evaluation of the risks of the ischemic events and bleeding is needed 
before the decision of an antithrombotic regimen. Second, NOACs are generally preferred 
to warfarin if anticoagulant therapy is required among AF patients with PCI. Third, in the 
periprocedural period, the combination of aspirin and clopidogrel is usually recommended, 
regardless of treatment strategy, provided that the risk of bleeding is not significantly high. 
Therefore, when AF patients requiring OAC receive PCI, both North American and European 
guidelines recommend NOAC-based TAT during the periprocedural period. Depending on 
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Figure 4. The impact of CHA2DS2-VASc or HAS-BLED scores on the preference of antithrombotic regimens. 
Multivariate logistic regression analysis based on the study population of 2018. CHA2DS2-VASc score of 0 and HAS-BLED score of 1 served as the reference in each 
analysis, respectively. 
CI = confidence interval; DAPT = dual antiplatelet therapy; OR = odds ratio.
the balance between the risk of ischemic events and bleeding, the period of TAT needed to 
be adjusted from 1 to 6 months individually. Afterward, NOAC-based DAT up to 12 months 
followed by NOAC monotherapy is recommended.21)
In this study, the proportion of patients receiving DAT was significantly small (<3%), 
and most received TAT or DAPT. We investigated which factors favored TAT or DAPT. 
Importantly, a high risk of bleeding (HAS-BLED score ≥3) did not have a significant 
association with the treatment choice, although a high HAS-BLED score should be used to 
identify and mitigate reversible bleeding risk factors and to identify high-risk patients for 
early review and follow-up.23) In contrast, a high risk of thromboembolism (CHA2DS2-VASc 
scores ≥2) was associated with TAT (Figure 3). The most important factor favoring DAPT 
was a history of intracranial hemorrhage, which was presumed to be due to the recurrence 
of hemorrhage, although DAPT has a similar risk of ICH as OAC.24) We found that DAPT was 
preferred if the patient had intracranial hemorrhage, renal disease, dyslipidemia, or vascular 
diseases, such as MI and peripheral arterial disease. We assume that more attention tends 
to be focused on the management of MI rather than stroke prevention in patients with AF 
who receive PCI for acute MI. Briefly, stroke risk factors favored TAT, whereas the covariates 
specific to the risk of bleeding favored DAPT. The covariates common to the risks of both 
stroke and bleeding favored TAT.
Non-Asians have a lower risk of major bleeding on administration of oral anticoagulants 
than Asians.25) Even in the Western populations, OACs in AF patients after PCI are 
underprescribed. In the CRUSADE registry of 1,648 patients with non-ST segment 
elevation MI and AF, only 27% were prescribed TAT, whereas 73% were prescribed DAPT at 
discharge.26) Such a suboptimal usage of OACs is considered to be affected by concerns of 
bleeding when prescribing TAT, specifically in elderly individuals. In another Danish study 
analyzing 12,165 AF patients with PCI from 2001 to 2009, the proportion of TAT was only 
accounted for in 15.6%.27)
The real-world data of non-Asians have been reported on antithrombotic therapy in patients 
with AF undergoing PCI.28) In the Danish nationwide registries from 2011 to 2017, NOAC 
with DAPT had a lower risk of bleeding than warfarin with DAPT, with a comparable risk of 
thromboembolism. Another Danish nationwide registries study from 2011 to 2016 found 
that the proportion of TAT had been increased (43% in 2011 to 60% in 2016), while that of 
DAT decreased.29) After the introduction of NOACs, warfarin-based therapy decreased, while 
NOAC-based therapy increased. Although DAPT was the most common antithrombotic 
regimen, this study did not provide the temporal trend of DAPT during the study period.
Consistent with the Danish study,28) we found that NOAC-based therapy outpaced warfarin-
based therapy from 2016, which was related to changes in the reimbursement criteria in 
Korea. Moreover, prescriptions of TAT increased, and those of DAPT decreased, but DAPT 
was the most preferred antithrombotic regimen in patients with AF undergoing PCI. Based 
on these studies, stroke prevention using OAC remains underutilized in AF patients with PCI 
among both Asian and non-Asian populations.
In Asia, OACs are more suboptimally prescribed in patients with AF undergoing PCI. One 
study investigated the temporal trends of antithrombotic therapy in Korean AF-PCI patients 
during 2006 and 2015, whereby the proportion of TAT increased from 22.7% to 38.2%, but 
DAPT still comprised the largest proportion at 60.3%.12) However, there is a caveat that this 
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study examined the antithrombotic regimen over the entire year of PCI, unlike the current 
study, which investigated only the regimen during the periprocedural period (i.e., within 
30 days after PCI). One real-world study from Taiwan also showed that DAPT was the most 
common regimen (72.0%), while TAT was used in only 15.0% of patients.30) Thus, despite 
several international guidelines that recommend NOAC-based TAT during the periprocedural 
period for AF-PCI patients, adherence to guidelines using OAC is still suboptimal despite 
the introduction of NOACs. The underuse of OACs appears to be due to concerns that 
adding warfarin to DAPT may increase the risk of bleeding, while the benefit of reducing 
thromboembolism is unclear among Asians. Since NOACs are rapidly replacing warfarin 
with better efficacy and safety for stroke prevention in patients with AF, there is the need to 
reconsider OAC-based therapy over DAPT in line with the recent evidences and guidelines. 
Meanwhile, we also found that most of NOACs were prescribed as reduced-dose (81.4% of 
total NOAC-based regimens in 2018) (Table 2). This pattern might reflect the concerns of 
bleeding for using triple therapy with regular-dose NOACs.
This study shares the limitations of other studies based on claims data. First, there may be a 
discrepancy between the prescriptions and the medications actually consumed by patients, 
and such a difference cannot be further evaluated in this study. For a given individual, 
the antithrombotic prescription chosen in this study was the one with the maximum 
combination of antiplatelet or anticoagulant drugs within 30 days after the PCI. Therefore, 
if OACs were prescribed prior to PCI, DAT or TAT may have been underestimated. Second, 
since this study used claims data, which lack detailed clinical information or medical records, 
we could not investigate the reasons for patients with DAPT not being prescribed OACs. 
Third, because this study is a cross-sectional observational study, it is not possible to confirm 
how the clinical outcome differs for each regimen. Fourth, the operational definition of the 
maximum combination of antithrombotic therapy might influence on the proportion of DAT. 
We analyzed the maximum combination of antithrombotic drugs prescribed within 30 days 
after PCI. Those who had changed from TAT to DAT within 30 days after PCI were regarded 
as the TAT group. Therefore, there is a chance that TAT may be over-estimated, whereas DAT 
might be under-estimated. If we consider a more extended period after one month from 
PCI, a higher proportion of DAT would be expected. This study focused on the treatment 
during the periprocedural period, and long-term therapy should be analyzed in a follow-up 
study. Lastly, it is challenging to estimate the duration of TAT accurately because of some 
differences in the date of claiming the reimbursement and prescription date.
After the introduction of NOACs for stroke prevention in AF, early periprocedural 
antithrombotic regimens in Korean patients with AF undergoing PCI have shifted toward less 
DAPT and more TAT. NOACs are increasingly used when OAC is prescribed; however, DAPT 
was still the most common regimen during the periprocedural period.
SUPPLEMENTARY MATERIALS
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